Home » Stocks » Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. (TNXP)

Stock Price: $1.15 USD -0.05 (-4.17%)
Updated Aug 7, 2020 1:52 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 144.61M
Revenue (ttm) n/a
Net Income (ttm) -29.66M
Shares Out 125.74M
EPS (ttm) -4.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.15
Previous Close $1.20
Change ($) -0.05
Change (%) -4.17%
Day's Open 1.18
Day's Range 1.14 - 1.19
Day's Volume 8,254,372
52-Week Range 0.39 - 5.89

More Stats

Market Cap 144.61M
Enterprise Value 113.87M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 125.74M
Float 52.29M
EPS (basic) -10.96
EPS (diluted) -4.52
FCF / Share -1.14
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.51M
Short Ratio 0.09
Short % of Float 1.15%
Beta 1.28
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.39
Revenue n/a
Operating Income -29.83M
Net Income -29.66M
Free Cash Flow -27.38M
Net Cash 30.74M
Net Cash / Share 0.24
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -69.11%
ROE -120.91%
ROIC 31,218.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $1.15
Target: 2.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.83-26.32-21.29-38.97-48.16-27.66-10.89-6.66-3.38-1.93
Net Income-28.62-26.09-21.12-38.84-48.05-27.62-10.88-9.45-3.47-1.96
Shares Outstanding1.610.1170.410.030.020.01----
Earnings Per Share-19.33-259.85-299.99-1,541.00-2,862.00-2,770.00-3,370.00-5,580.00-3,240.00-3,600.00
Operating Cash Flow-26.68-23.97-19.13-37.31-42.53-22.84-8.52-5.71-2.64-1.23
Capital Expenditures-0.02-0.01-0.01-0.07-0.24-0.32-0.02-0.04--0.03
Free Cash Flow-26.70-23.98-19.13-37.38-42.77-23.16-8.53-5.75-2.64-1.27
Cash & Equivalents11.3525.1325.5926.2143.1538.328.261.850.100.13
Total Debt0.01-----0.28-2.08-
Net Cash / Debt11.3425.1325.5926.2143.1538.327.981.85-1.970.13
Book Value9.4223.6624.6225.3640.2636.096.510.96-2.45-0.18
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tonix Pharmaceuticals Holding Corp.
Country United States
Employees 16
CEO Seth Lederman

Stock Information

Ticker Symbol TNXP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TNXP


Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing drugs and biologics to treat various diseases. Its lead product candidate is TNX-102 SL, a proprietary cyclobenzaprine HCl sublingual tablets as a bedtime administration, which is in Phase III clinical trial for the treatment of posttraumatic stress disorder (PTSD) and fibromyalgia; Phase II development for the treatment of agitation in Alzheimer's disease; and Phase II proof-of-concept study for the treatment of alcohol use disorder. The company is also developing TNX-601 (tianeptine oxalate) that is in pre-investigational new drug application stage for the treatment of PTSD and neurocognitive dysfunction associated with corticosteroid; TNX-1300 for the treatment of cocaine intoxication; and TNX-801, a smallpox-preventing vaccine, which is in preclinical stage based on synthetic version of live horsepox virus. In addition, its other preclinical product candidates include TNX-1600 for the treatment of PTSD, and depression and attention deficit hyperactivity disorder; TNX-1500 for prevention and treatment of organ transplant rejection, as well as for autoimmune conditions, such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis; and TNX-1700 for gastric and pancreatic cancers. Tonix Pharmaceuticals Holding Corp. has a research collaboration agreement with Massachusetts General Hospital for testing TNX-1500 for the prevention of organ transplant rejection; and a strategic collaboration with Southern Research Institute to support the development of TNX-1800, a vaccine to protect against COVID-19. The company was founded in 2007 and is based in New York, New York.